- Home
- FLNG vs ANAB Comparison
FLNG vs ANAB Comparison
Compare FLNG & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNG | ANAB |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | FLNG | ANAB |
|---|---|---|
| Price | $24.96 | $51.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $23.00 | ★ $59.90 |
| AVG Volume (30 Days) | 385.8K | ★ 423.3K |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 12.23% | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $351,034,000.00 | $169,467,000.00 |
| Revenue This Year | N/A | $135.45 |
| Revenue Next Year | $2.85 | N/A |
| P/E Ratio | $13.48 | ★ N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $19.46 | $12.21 |
| 52 Week High | $27.67 | $51.43 |
Technical Indicators
Market Signals| Indicator | FLNG | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 79.13 |
| Support Level | $24.14 | $49.50 |
| Resistance Level | $25.60 | $51.43 |
| Average True Range (ATR) | 0.42 | 2.22 |
| MACD | -0.07 | 0.25 |
| Stochastic Oscillator | 46.27 | 91.93 |
Price Performance
Historical ComparisonAbout FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).